A study evaluating safety and efficacy of Apatinib for advanced non small cell lung cancer in the second- or third-line setting.
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record